type_2_diabetes_28081593711

Type 2 diabetes cases up 40% in Scotland

pharmafile | February 11, 2020 | News story | Manufacturing and Production Type 1 diabetes, diabetes, diabetes obesity, obesity, type 2 diabetes 

According to a new study, Scotland’s cases of type 2 diabetes has increased by 40% over the last 10 years.

Diabetes Scotland’s figures show cases rose from 190,772 to 267,615 between 2008 and 2018. They also estimate that 26,347 people are living with the condition.

Diabetes Scotland said the figures prove this is now an urgent public health crisis. Angela Mitchel, the Director of the organization, said: “Solving the crisis depends on decisive action led by both the UK and Scottish governments, supported by industry and delivered across our society.

“We must create healthy environments which support people to make healthy choices. This includes mandating industry to make food and drinks healthier and addressing the marketing and promotion of unhealthy foods. We welcome the action from the Scottish government in developing the Type 2 Diabetes Framework but we must ensure that there is long-term support people in Scotland to live healthier lives.”

People with Type 2 diabetes face a greatest chance of premature death than the general population, by about 50%. Heart disease is a common complication, with overweight type 2 diabetics affected in particular.

Type 2 diabetes is a chronic condition associated with both obesity and is particularly common in older people, with excessive weight being responsible for 80%85% of people developing the condition.

Conor Kavanagh

Related Content

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Roche shares data on novel solution for continuous glucose monitoring

Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …

Latest content